Digestive Diseases and Sciences

, Volume 39, Issue 5, pp 957–960 | Cite as

Attenuation of acetaminophen hepatitis by prostaglandin E2

A histopathological study
  • George L. Monto
  • Peter J. Scheuer
  • Ronald L. Hansing
  • Andrew K. Burroughs


Acute acetaminophen hepatitis was produced in three groups of five rats given 1600 mg/kg by gavage. The protective effect of 16,16-dimethyl prostaglandin E2, 200 µg/kg administered subcutaneously 30 min later, was compared to the protective effect ofN-acetylcysteine 1 g/kg similarly administered. All animals were killed at 24 hr, and liver tissues were compared histologically to the damage found in acetaminophen-treated controls and untreated anatomic controls. Serum transaminase values at 24 hr exceeded 1000 units in the acetaminophen control group, averaged 658 units in the acetylcysteine treated group, and were near normal (75 units) in the prostaglandin treated group (P<0.02). Liver samples (1 cm3) were removed terminally at 24 hr. Liver damage was assessed without reference to precedent history. Histopathologically, damage was most severe in the acetaminophen control group, mainly in pericentral lobular zones. The prostaglandin-treated group showed considerably less damage, which was confined to the hepatic vein area. The acetylcysteine-treated group showed an intermediate degree of damage. We conclude that dmPGE2, given 30 min after ingestion of acetaminophen was found to be more effective in limiting liver damage than NAC in this rat model.

Key words

histopathology acetaminophen hepatitis dimethyl prostaglandin E2 N-acetylcysteine pericentral necrosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lefer AM, Smith EF: Protective action of prostacyclin in myocardial ischemia and trauma.In Prostacyclin. JR Vane, S Bergstrom (eds). New York, Raven Press, 1979, p 339Google Scholar
  2. 2.
    Ruwart MJ, Rush BD, Friedle NM, Piper RC, Kolaja GJ: Protestive Effects of 16,16-dimethyl PGE2 on the liver and kidney. Prostaglandins 21(suppl):87–96, 1980Google Scholar
  3. 3.
    Stachura J, Tarnawski A, Szczudrawa J, et al: Cytoprotective effect of 16,16-dimethyl prostaglandin E2 and some drugs on an acute galactosamine induced liver damage in rat. Folia Histochem Cytochem 9:311–318, 1980Google Scholar
  4. 4.
    Rush BD, Wilkinson KF, Nichols NM, Ochoa R, Brunden MN, Ruwart JM: Hepatic protection by 16,16-dimethyl prostaglandin E2 (DMPG) against acute aflatoxin B1 injury in the rat. Prostaglandins 37:683–693, 1989PubMedGoogle Scholar
  5. 5.
    Corcoran GB, Racz WN, Smith CV, Mitchell JR: Effects of acetylcysteine on acetaminophen covalent binding and hepatic necrosis of mice. J Pharmacol Exp Ther 223(3):864, 1985Google Scholar
  6. 6.
    O'Grady JG, Alexander GJ, Hayllar KM, Williams R: Early indicators of prognosis infulmanent hepatic failure. Gastroenterology 97:439, 1989PubMedGoogle Scholar
  7. 7.
    Insel PA: Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout.In The Pharmacological Basis of Therapeutics. AG Gilman, TR Rall, AS Nies, P Taylor (eds). New York, Pergamon Press, 1990, p 657Google Scholar
  8. 8.
    Wroblewski F, LaDue JS: Serum glutamic pyruvic transaminase in cardiac and hepatic diseases. Proc Soc Exp Biol Med 91:569–574, 1956PubMedGoogle Scholar
  9. 9.
    Siegel N, Castellan NJ: Nonparametric Statistics. New York, McGraw-Hill, 1988, p 128Google Scholar
  10. 10.
    Orrego H, Carmichal FJ, Phillips MJ, et al: Protection by propyl thiouracil against carbon tetrachloride-induced liver damage. Gastroenterology 71:821, 1976PubMedGoogle Scholar
  11. 11.
    Llewelyn-Jones D: Fundamentals of Obstetrics and Gynaecology. London, Faber, 1986, p 148Google Scholar
  12. 12.
    Sherlock S: Diseases of the Liver and Biliary System. Oxford, McGraw-Hill, 1988Google Scholar
  13. 13.
    Reynolds ES, Yee AG: Liver parenchymal cell injury. V. Relationship between patterns of chloromethane incorporation into constituents of liver in vivo and cellular injury. Lab Invest 16:591–603, 1967PubMedGoogle Scholar
  14. 14.
    Recknagel RO, Rees KR: Lipid peroxidation as a vector in carbon tetrachloride hepatotoxicity. Lab Invest 15:132–148, 1966PubMedGoogle Scholar
  15. 15.
    Burk RF: Hepatoprotective substances. Gastroenterology 81:397–398, 1981PubMedGoogle Scholar
  16. 16.
    Masaki N, Ohta Y, Shirataki H, et al: Hepatocyte membrane stabilization by prostaglandins E1 and E2: Favorable effects on rat liver injury. Gastroenterology 102:572–576, 1992PubMedGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1994

Authors and Affiliations

  • George L. Monto
    • 1
    • 2
  • Peter J. Scheuer
    • 1
    • 2
  • Ronald L. Hansing
    • 1
    • 2
  • Andrew K. Burroughs
    • 1
    • 2
  1. 1.From the Academic Departments of Medicine and Histopathology, Royal Free Hospital School of MedicineUniversity of LondonLondonUK
  2. 2.Department of PathologyColmery-O'Neil Veterans Administration HospitalTopeka

Personalised recommendations